Home > Oncology > ASCO 2022 > New standard-of-care for cisplatin-ineligible LAHNSCC

New standard-of-care for cisplatin-ineligible LAHNSCC

Presented By
Prof. Vanita Noronha, Tata Memorial Hospital, India
ASCO 2022
Docetaxel added to radiation improved the disease-free survival (DFS) and overall survival (OS) of patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current randomised trial is the first study to assess docetaxel as a radiosensitiser in cisplatin-ineligible patients with LAHNSCC and resulted in the presentation of a new reference standard-of-care for this population. Although chemoradiation with cisplatin is a main standard therapy for patients with LAHNSCC, patients who are unsuitable to receive cisplatin are not uncommon. Prof. Vanita Noronha (Tata Memorial Hospital, India) discussed the phase 3 trial that randomised patients with LAHNSCC, who were ineligible for cisplatin, to radiotherapy alone (n=176) or docetaxel and radiotherapy (n=180) [1]. The main outcomes of the trial were DFS and OS after 2 years, quality of life, and adverse events (AEs). The 2-year DFS was significantly higher in participants wh...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on